Figure 1 (Alendronate Fig1)
Alendronate Sodium Tablet
Product Images NDC 50090-3126
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 50090-3126). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2 (Alendronate Fig2)
This is a table showing the increase in bone mineral density (BMD) in postmenopausal women with osteoporosis after three years of treatment with Alendronate 10 mg/day. The BMD increase is listed as a mean percentage increase relative to placebo and is shown for three different areas of the body: the lumbar spine, femoral neck, and trochanter. The table also includes reference numbers, but they are not readable due to errors.*
Figure 3 (Alendronate Fig3)
Description: This appears to be a graph from a study on Osteoporosis treatment in postmenopausal women. The graph compares the effect of alendronate 10mg/day versus a placebo on Lumbar Spine BMD Percent Change From Baseline over a period of 36 months. However, the information provided is limited and difficult to interpret without further context.*
Figure 4 (Alendronate Fig4)
Studies In Glucocorticoid (Treated Patients Increase in BMD Alendronate 5 mg/day at One Year)
Studies In Paget's Disease Of Bone Effect On Serum Alkaline Phosphatase Of Alendronate 40 mg/day Versus Placebo Or Etidronate 400 mg/day (Alendronate Fig6)
This document presents the effect of Alendronate 40 mg/day on serum alkaline phosphatase in patients with Paget's Disease of Bone in comparison to Placebo or Etidronate 400 mg/day, based on multinational and U.S. studies. It includes a graph showing the mean % change from baseline over a period of 6 months.*
Chemical Structure (Alendronate Str)
Label Image (Lbl500903126)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
